Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study.
about
New tricks from an old oncogene: gene fusion and copy number alterations of MYB in human cancerAdenoid cystic carcinoma: current therapy and potential therapeutic advances based on genomic profilingEpithelial tumours of the lacrimal gland: a clinical, histopathological, surgical and oncological surveyManagement of salivary gland carcinomas - a reviewA Phase II study of Dovitinib in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma.Adenoid cystic carcinoma: A review of recent advances, molecular targets, and clinical trials.Genetic profiling reveals cross-contamination and misidentification of 6 adenoid cystic carcinoma cell lines: ACC2, ACC3, ACCM, ACCNS, ACCS and CAC2.Primary intraosseous ACC of mandible of possible salivary origin: A rare clinical entityTreatment of c-kit positive adenoid cystic carcinoma of the tongue: A case reportA phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma.Combined treatment of adenoid cystic carcinoma with cetuximab and IMRT plus C12 heavy ion boost: ACCEPT [ACC, Erbitux® and particle therapy].Mutations in the c-Kit gene disrupt mitogen-activated protein kinase signaling during tumor development in adenoid cystic carcinoma of the salivary glandsRadioImmunotherapy for adenoid cystic carcinoma: a single-institution series of combined treatment with cetuximab.Cell type-dependent biomarker expression in adenoid cystic carcinoma: biologic and therapeutic implicationsc-Kit Expression is Rate-Limiting for Stem Cell Factor-Mediated Disease Progression in Adenoid Cystic Carcinoma of the Salivary Glands.A multicenter phase II study of everolimus in patients with progressive unresectable adenoid cystic carcinoma.The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors.MYB expression and translocation in adenoid cystic carcinomas and other salivary gland tumors with clinicopathologic correlation.A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303).Efficacy of sorafenib, a multi-tyrosine kinase inhibitor, in an adenoid cystic carcinoma metastatic to the lung: case report and review of literaturePrimary pulmonary adenoid cystic carcinoma: clinicopathological analyses of 12 casesMetastatic Salivary Gland Tumors: A Single-Center Study Demonstrating the Feasibility and Potential Clinical Benefit of Molecular-Profiling-Guided Therapy.Parotid carcinoma: Current diagnostic workup and treatment.Adenoid cystic carcinoma of the parotid glandAmerican Society of Clinical Oncology 41st annual meeting.Targeted next generation sequencing of parotid gland cancer uncovers genetic heterogeneity.MicroRNA-101-3p suppresses cell proliferation, invasion and enhances chemotherapeutic sensitivity in salivary gland adenoid cystic carcinoma by targeting Pim-1.Prognostic value of expression of molecular markers in adenoid cystic cancer of the salivary glands compared with lymph node metastasis: a retrospective studyMalignancies of the head and neck: the role for molecular targeted agents.Advances in salivary gland pathology.Small molecule signal transduction inhibitors for the treatment of solid tumors.Prioritizing phase I treatment options through preclinical testing on personalized tumorgraft.Identification of c-kit gene mutations in primary adenoid cystic carcinoma of the salivary gland.Systemic therapies for recurrent and/or metastatic salivary gland cancers.Salivary gland cancers: current treatments, molecular characteristics and new therapies.New agents in the treatment for malignancies of the salivary and thyroid glands.Mutation profiling of adenoid cystic carcinomas from multiple anatomical sites identifies mutations in the RAS pathway, but no KIT mutations.Cetuximab and platinum-based chemoradio- or chemotherapy of patients with epidermal growth factor receptor expressing adenoid cystic carcinoma: a phase II trial.Adenoid cystic carcinoma of the tongue--clinicopathological study and survival analysis.Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib
P2860
Q24620308-6DDCAA96-417C-4CBD-BA81-62D89D3E187EQ26781643-2C6A6DCD-4F15-421B-A949-15E55FC75677Q27025842-C1EBF1C2-5BE3-4699-ABBF-50D83D62E4BCQ28069083-4A18D03F-7F87-4B5A-97CD-4131DB2F5B09Q30252721-D24C8AC0-388D-4365-8C58-218F0F942334Q30301145-76CBD3BF-CF24-413E-9D7D-79214CEC3F4AQ33474850-ECF20923-2A51-4B9D-A64F-DF13C9F204D8Q33561605-0C8A9832-0070-4CEE-82A9-4A3512D7E3F5Q33778358-F48C102A-F6B0-4FD1-A341-573FB06C95D9Q33779308-69997413-E057-447C-A039-0F95C662CC5CQ33820302-1165A291-2564-4E83-8D57-6055C09AC5E1Q34105349-657FF97D-F13A-48F0-BEB3-AE0529C95CBDQ34331751-79609F54-ED6D-4F20-9930-424C8281BAE2Q34388573-1E258817-812D-4BF0-9BF0-94CAC4816786Q34478359-59EC810C-E964-419F-84EF-77A9AB75FB2FQ34491238-7F702B17-CC70-47AC-9287-A030EEAED834Q34725749-779CBF0C-B30E-4F62-9003-907B51F25348Q35079608-7785C6C2-9065-4CEC-968E-EC24FE7937F4Q35103364-D664323D-0508-4B96-B012-39A04D445A35Q35318748-B869086E-B883-48EA-B7E5-957C8834DD24Q35919602-CB523F32-13BD-4C18-A875-78AF0651BF9AQ36095613-F29597AC-1288-480A-95D0-24B15BC4FC51Q36170033-67832233-2459-465C-8742-DA45B74DAA9AQ36181635-C6D89BF7-6B4A-4BA8-921C-7B4A25C7D8CBQ36210888-F9D1239F-98F1-4E06-B129-79FCEFDAC52EQ36228558-0DC1C29A-00CC-448B-A2E5-924D2D62A8F6Q36309379-DD4ED307-FB71-4E91-AC57-AFC69BE02A13Q36565198-B426E89E-FC8F-4B7F-B8F3-7635FC344FBDQ36709551-451167B3-CA93-48FE-B8E3-F0FC40D26DACQ36835992-8233BE79-CF46-445C-B843-0273424FD0BFQ36895413-2DE885C0-BA38-4986-B17D-1746E69C7E82Q36920470-17C68394-E6E4-476B-A31C-8B49597A4885Q37101469-54630C88-73D8-4D6C-8CCC-44236787A233Q37118940-5FF134CD-3A74-4A87-B576-42EC3445CE37Q37134463-AE0D1BD5-06BC-46E3-9E38-31F90B0C9D40Q37137859-910E3F40-9453-4417-9675-640D67572E9EQ37155712-71AD4829-6DC2-4BA1-A595-F702FDC904FBQ37185867-97B8649F-039B-4E5A-A1FF-95E4DC01A1EFQ37223575-C2BD3C50-4778-49C7-A46B-05291B2FC069Q37265167-614E5B7D-73FE-4293-BA2A-094F8B4D5CA5
P2860
Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Imatinib mesylate in patients ...... tal phase II consortium study.
@en
Imatinib mesylate in patients ...... tal phase II consortium study.
@nl
type
label
Imatinib mesylate in patients ...... tal phase II consortium study.
@en
Imatinib mesylate in patients ...... tal phase II consortium study.
@nl
prefLabel
Imatinib mesylate in patients ...... tal phase II consortium study.
@en
Imatinib mesylate in patients ...... tal phase II consortium study.
@nl
P2093
P356
P1476
Imatinib mesylate in patients ...... tal phase II consortium study.
@en
P2093
Anthony Murgo
Elizabeth Lamont
Eric W Winquist
Eric X Chen
Gregory R Pond
Lillian L Siu
Mary MacKenzie
Shirley Brown
Sébastien J Hotte
P304
P356
10.1200/JCO.2005.06.125
P407
P577
2005-01-01T00:00:00Z